Nimish A. Mohile, M.D.

Biography

Awards

2015
A. B. Baker Teacher Recognition Award
Sponsor: American Academy of Neurology

2011
SWOG Travel Award Recipient
Sponsor: Southwest Oncology Group

VIEW ALL expand_more

Clinical Trials

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy,A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

Lead Researcher: Nimish A Mohile

This is a dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally (between the skin layers) or subcutaneously (under the skin) in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase. Once the highest dose with acceptable toxicity is determined from either the intradermal or subcutaneous group, an additional 40 patients may be enrolled as an expansion cohort at this dose and route of administration to confirm safety and tolerability. Separate from the dose-ascending cohort and expansion cohort described previously, and once the intradermal dose-ascending cohort is completed, up to 20 myelodysplastic syndrome (MDS) patients who are resistant to treatment with hypomethylating agents (HMAs) will be enrolled into an MDS expansion cohort. Of these 20 MDS patients, one-half will receive DSP-7888 at 10.5 mg according to the modified schedule employed in Phase 1 (every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks [Named MDS Cohort 1]). The other half of the MDS patients will receive DSP-7888 at 10.5 mg in an alternative dosing schedule where DSP-7888 is administered every 2 weeks until Week 24, after which it will be administered every 4 weeks (Named MDS Cohort 2).

View Study Details

Publications

Journal Articles

1/2017
Gewandter JS, Dworkin RH, Finnerup NB, Mohile NA. "Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology?" Pain.. 2017 Jan 0; 158(1):30-33.

1/2017
Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J. "A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma." CNS oncology.. 2017 Jan 0; 6(1):29-43. Epub 2016 Sep 15.

9/2016
Herr MM, Mohile NA, Barr PM, van Wijngaarden E, Brown EB, Rich DQ. "Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2016 Sep 0; 16(9):e123-e127. Epub 2016 Jun 08.

Books & Chapters

2007
Chapter Title: Principles of Chemotherapy
Book Title: Brain Tumors: Practical Guide to Diagnosis and Treatment
Author List: Abrey LE and Mohile NA
Edited By: Baehring J, Piepmeier J
Published By: Informa Health Care, USA 2007 in New York

2006
Chapter Title: Chemotherapy of Neuronal Tumors
Book Title: Handbook of Brain Tumor Chemotherapy
Author List: Mohile, N.A.; Raizer, J.J.
Edited By: Newton, H.B.
Published By: Elsevier 2006 in Amsterdam: Boston

VIEW ALL PUBLICATIONS